bioMérieux Records 7.3% Organic Growth Over the First Nine Months of 2025
bioMérieux has announced a 7.3% increase in organic sales growth for the first nine months of the year, reaching 2,992 million euros, according to the press release.
According to information provided by bioMérieux, consolidated sales for the first nine months of 2025 reached 2,992 million euros, representing a growth of 4.2% compared to the same period last year, where sales amounted to 2,871 million euros. This increase includes an organic growth of 7.3%, although the impact of currency effects was negative, representing a decrease of 85 million euros. In terms of quarterly performance, the company observed an organic sales growth of 3% in the third quarter, affected by a double-digit decline in China and an 8% drop in sales of BIOFIRE® respiratory panels, a segment influenced by low epidemiological activity.
Expansion of Product Portfolio and Installed Base
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
bioMérieux continues to expand its installed base, particularly for its BIOFIRE® and SPOTFIRE® systems, which have shown growths of 9% and 114% respectively over the first nine months. The company also obtained FDA 510(k) clearance and CLIA waiver for its SPOTFIRE® R/ST Panel Mini test, thereby enhancing its diagnostic offerings. Additionally, bioMérieux launched GENE-UP® PRO HRM, a new quality control solution based on DNA detection of thermoresistant molds. These actions are part of the strategic plan GO•28 aimed at continuous profitability improvement.
2025 Forecasts Adjusted
bioMérieux has adjusted its forecasts for 2025, expecting an organic revenue growth between 5.5% and 6.5% at constant exchange rates, thus revising its previous forecasts downward due to a late respiratory season. However, the company maintains its growth forecasts for current contributory operating income (ROCC), which is expected to increase between 12% and 18%, also at constant exchange rates. Nevertheless, currency effects are expected to negatively impact annual CEBIT by 30 million euros. In terms of regions, North America and Latin America show positive dynamics, while Asia-Pacific, particularly China, records performance declines.
SectorDiagnostic et services de laboratoire›Diagnostic / labos d'analyse
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: S1 2026
Key reported figures
Revenue: 1 965 millions d'euros
Quarterly revenue: 1 965 millions d'euros
Revenue growth: -3,9 %
EBITDA: 440,3 millions d'euros
EBITDA margin: 22,4 %
Net income: 226,1 millions d'euros
Free cash flow: 299 millions d'euros
-235,9 millions d'euros
Guidance from the release
confirme ses perspectives pour 2026 : croissance organique du chiffre d'affaires comprise entre +3% et +5%, CEBIT croissance comprise entre 0% et +10%
Risks mentioned
Épidémiologie respiratoire plus faible : recul organique de 17 % des panels respiratoires BIOFIRE®
Effet de change défavorable de 35 M€ sur le ROCC du premier semestre 2026
Environnement géopolitique et macroéconomique dégradé depuis 2024
Opportunities identified
Croissance organique de 6 % des quatre moteurs de croissance du plan GO•28
Dépôt auprès de la FDA du panel SPOTFIRE® Vaginitis
Obtention du marquage CE du premier test SPINCHIP®
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
